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Autologous stem cell transplantation (ASCT) is commonly
used in relapsed or refractory non-Hodgkin's lymphoma
(NHL). Several trials report the role of ASCT for high risk
patients. We evaluated the results and the prognostic factors
influencing the therapeutic effects on the patients who were
treated with high dose chemotherapy (HDC) and autologous
peripheral stem cell transplantation. We analyzed the data of
40 cases with NHL who underwent ASCT after HDC. Twenty-
four patients had high-risk disease, 12 cases sensitive relapse,
and two cases resistant relapse or primary refractory each. The
median age of patients was 34 years (range, 14-58 years). The
median follow-up duration from transplantation was 16
months (range, 0.6-94 months). Estimated overall survival and
progression-free survival at 5 years were 40% and 30%,
respectively. Poor prognostic factors for survival included
older age ( 45 years), poor performance status in all patient
analysis, and a longer interval between first complete
remission and transplantation in high risk patients. In high risk
NHL patients, transplantation should be done early after first
complete remission to overcome chemo-resistance.
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non-Hodgkin
INTRODUCTION
The regimen of cyclophosphamide, doxorubicin,
vincristine, and predisolone (CHOP) is the stan-
dard initial treatment for disseminated aggressive
lymphoma in adults, and currently monoclonal
antibody has become part of standard treatment
in CD20+ non-Hodgkin’s lymphoma (NHL).1,2
Conventional combination chemotherapy can in-
duce a completion remission (CR) in about 60
percent of patients with disseminated interme-
diate-grade or high-grade NHL.3 However,
sustained remission after the first line of therapy
is only achieved in 40-50% of unselected patients.3
Other intensive third-generation regimens did not
prove to be better than CHOP.4 Although a
variety of salvage chemotherapy protocols have
been developed, reported long-term survival rates
range less than 10%.5 Since the 1980s, certain
reports have indicated that high-dose chemo-
therapy (HDC) with autologous stem cell trans-
plantation (ASCT) may be superior to conven-
tional therapy in selected younger patients with
aggressive lymphoma.6,7 At present, HDC with
ASCT is the treatment of choice for patients with
relapsed aggressive NHL.8 The role of HDC with
ASCT as part of the initial therapy for high-risk
patients is promising but not yet conclusively
determined.9-15 Furthermore, recently reported
and ongoing trials are studying the role of ASCT
in patients with low-grade NHL.
16,17
We report here a retrospective analysis of 40
patients who underwent autologous peripheral
stem cell transplantation after HDC in Severance
Hospital between 1996 and 2004.
MATERIALS AND METHODS
A total of 40 patients diagnosed with NHL were
included in this study. Criteria for ASCT were
patients with any of the following conditions:
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those relapsed but chemo-sensitive, those who
had not achieved CR but were chemo-sensitive,
those who were relapsed and chemo-resistant;
those who were primary refractory to salvage
chemotherapy, or patients considered to have a
high risk of relapse according to the International
Prognostic Index (IPI). The high risk group had a
lower chance of being cured with standard induc-
tion therapy and were defined as responding to
first-line chemotherapy and by fulfilling at least
one of the following criteria: stage III or IV,18
bulky disease or elevated lactate dehydrogenase
(LDH).15 The high risk group included patients
who achieved their first CR after induction
chemotherapy and patients who failed to achieved
CR after induction therapy but showed partial
response (PR). Chemotherapy sensitivity was
defined as a reduction in measurable disease with
salvage chemotherapy that exceeded the PR
criteria. Chemo-sensitive patients included sensi-
tive-relapse patients who relapsed after induction
therapy. Primary-refractory disease was defined
as a stable or progressive disease documented at
restaging immediately after the completion of
induction therapy.19 Other inclusion criteria were
as follows: diagnosis of NHL confirmed by his-
topathologist; age between 14 and 60 years;
normal liver, kidney, heart, and pulmonary func-
tion on the basis of routine clinical and laboratory
examinations; radionuclide ventriculography or
echocardiography; lung-function tests; and an
Eastern Cooperative Oncology Group perform-
ance status (ECOG) of 0 through 2. Informed
consent was obtained from all patients.
Transplant procedure
As the first line treatment, 55% of the patients
received CHOP, and response to first-line treat-
ment was as follows: CR in 28 patients (70%), PR
in 8 patients (20%) and no response in 4 patients
(10%).
Autologous progenitor cells were mobilized
with peripheral blood by using mobilization
chemotherapy and granulocyte colony stimulating
factor (G-CSF). Thirty-seven patients (92%) were
conditioned with BEAM (carmustine, etoposide,
cytarabine and melphalan) and 3 patients (8%)
were conditioned with BEAC (carmustine, etopo-
side, cytarabine and cyclophosphamide). After
conditioning regimen autologous stem cells were
infused. Daily G-CSF 300 g/mμ 2/day subcuta-
neously starting d+5 and continuing until an
absolute neutrophil count of > 1,000/ L for 3μ
consecutive days or > 10,000/ L. Patients reμ -
ceived supportive care, including hydration, pro-
phylactic oral antibacterial and antifungal treat-
ment, and acyclovir was administered at 15
mg/kg/day from d-9 until neutrophil recovery.
Intravenous globulin 500 mg/kg was adminis-
tered at d-9, d-3, d+1 and the weekly until d+56
then biweekly until d+120. Patients were trans-
fused with irradiated blood products to maintain
a platelet count > 50,000/ L and hematocrit >μ
30%.
Response criteria
The clinical and radiological staging after HDC
with ASCT was evaluated at 3 months. Complete
remission was defined as complete tumor dis-
appearance, and partial remission as the reduction
of measurable disease by 50% of tumor area
without the appearance of any new lesions. No
response was defined as unmodified disease after
the transplant or the appearance of new lesions.
After ASCT, engraftment was confirmed by an
increase of WBC to more than 500/ L and anμ
increase of platelet level to more than 50,000/ L.μ 20
Toxicity was assessed using the World Health
Organization toxicity criteria.
Statistical analysis
The survival curve was calculated according to
the Kaplan-Meier method. Overall survival (OS)
was calculated from the day of stem cells infusion
to the date of death or last follow-up.
21
Progres-
sion-free survival (PFS) was calculated from the
day of stem cells infusion until the date of relapse
or progression.
21
In order to analyze which factors
influence OS and PFS, clinical and laboratory
factors at diagnosis and transplantation were
included in the univariate analysis. Those factors
with a statistically significant influence on OS or
PFS determined by univariate analysis were in-
cluded in a multivariate analysis. These variables
are specified in Table 1 and 2. The log-rank test
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was used to estimate the differences in survival
between groups according to the different
covariates. All reported p values are two-sided
and the value of p < 0.05 was considered signifi-
cant. Factors that were predictive of OS and PFS
in the univariate analysis were calculated using
the Cox proportion hazards model for multi-
variate analysis. Statistical analyses were per-




Forty patients with NHL were analyzed. At the
time of diagnosis, patients' ages ranged from
14-58 years, with a median age of 34 years. Of the
pathologic diagnoses, diffuse large B cell were
identified in 60% of patients, lymphoblastic B cell
lymphoma in 17.5% and other diagnoses in 22.5%
Table 1. Patient Characteristics at Diagnosis
Characteristics No. of patients % Characteristics No. of patients %
Sex Stage
Male 30 75 I/II 5 12
Female 10 25 III/IV 35 88
Age (yrs) ECOG
45 30 75 0 - 1 39 98
> 45 10 25 2 1 2
Histology LDH
DLBC 24 60 100% 14 35
PTC 2 5 > 100% 21 65
Lymphoblastic 7 17.5 AA-IPI
Anaplastic 3 7.5 0 2 5
Follicular 3 7.5 1 16 46
Angioimmuno 1 2.5 2 17 49
3 0 0
Cell phenotype Bone marrow
B-cell 29 72.5 Uninvolved 30 75
T-cell 11 27.5 Involved 10 25
Extranodal site Bulky disease
0 13 33 < 10 cm 30 75
1 15 37 10 cm 10 25
2 12 30
β2-microglobulin
< 100% 17 56
100% 13 44
DLBC, diffuse large B cell lymphoma; PTC, peripheral T cell lymphoma; Lymphoblastic, lymphoblastic lymphoma; Anaplastic, anaplastic
T cell lymphoma; Follicular, follicular lymphoma; Angioimmuno, angioimmunoblastic T-cell lymphoma; ECOG, Eastern Cooperative
Oncology Group performance status; LDH, lactate dehydrogenase; AA-IPI, age-adjusted International Prognostic Index.
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(Table 1). At the time of initial diagnosis, 98% had
ECOG 0 or 1, 88% of patients had stage III or IV
disease, and 21 (60%) of 35 assessable patients had
an elevated LDH level. Ten (25%) patients had
bulky disease at diagnosis ( 10 cm). Twenty-two
patients (55%) received CHOP regimen for remis-
sion induction. Complete remission was achieved
in 35 patients (87.5%), and of these, 14 patients
(40%) relapsed before transplantation. Salvage
chemotherapy included MiCMA (mitoxantrone,
carboplatinum, methylpredisolone, cytarabine):
30%, ESHAP (etoposide, methylpredisolone,
cytarabine, carboplantinum): 15%, HOAP-Bleo
(adriamycin, vincristine, cytarabine, predisolone,
bleomycin): 15%, IMVP-16 (ifosfamide, metho-
trexate, etoposide) and FND (fludarabine,
mitoxantrone, dexamethasone).
At the time of transplantation, patients' ages
ranged from 15-59 years, with a median age of 36
years. We divided the 40 patients into 4 groups
according to the disease status before trans-
plantation; 24 patients with high risk disease, 12
with sensitive relapsed disease, 2 with resistant
relapsed, and 2 in primary-refractory status. Nine
(82%) of the sensitive relapsed patients and 2
(100%) of the resistant relapsed patients were in
the high risk group at diagnosis (Table 2).
Engraftment and recovery of WBC and platelets
The median number of infused CD34+ cells was
12.5 × 106/kg (range, 4.0-543.0 × 106/kg). The
median time to a WBC count > 500/ L was 9 daysμ
(range, 7-18 days) and to > 1000/ L, 10 daysμ
(range, 7-26 days). The median time to a platelet
count of > 50,000/ L was 12 days (range, 0-27μ
days) and to 100,000/ L, 17 days (range, 8-186μ
days). Treatment-related death occurred in one
patient (2.2%), as a result of veno-occlusive
disease. Severe grade 3/4 mucositis and diarrhea
were observed in 5% and 5% respectively, and
grade 3/4 nausea, vomiting, liver toxicity in 2.5%,
2.5%, 2.5%, respectively.
Response to ASCT and survival rate
The overall response rate to ASCT after 3
months was 70%. In high risk patients (21 patients
in first CR after induction therapy, 3 patients in
chemo-sensitive but not reach CR), 83.3% (20
cases) remained or achieved on CR, and 16.7%
(four cases) had recurrence or not achieve CR. In
patients transplanted at sensitive relapse (12
patients), 58.3% reached CR and of the patients
with resistant relapse, 50% achieved CR. In the
two patients that transplanted in refractory
disease, one patient reached CR, and the other did
not respond.
The median follow-up period from transplanta-
tion was 16 months (range 0.6-94 months). The
median OS and PFS were 28 and 27 months,
Table 2. Patient Characteristics at Transplantation






Range 15 - 59
45 28 70
> 45 12 30
Status
High risk 24 60
Sensitive relapse 12 30
Resistant relapse 2 5
Primary refractory 2 5
LDH
100% 26 65




Interval in high risk patient
4 months 17 81
> 4 months 4 19
LDH, lactate dehydrogenase; BEAM, carmustine, etoposide,
cytarabine and melphalan; BEAC, carmustine, etoposide,
cytarabine and cyclophosphamide; Interval, interval from first
CR to transplantation in high risk patients.
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respectively. OS and PFS rate were 40.0% (95% CI:
30.0-50.0%), 30.0% (95% CI: 19.0-41.0%) at 5 years,
and were 40.0% (95% CI: 30.0-50.0%) and 30.0%
(95% CI: 19.0-41.0%) at 8 years, respectively (Fig.
1). The OS and PFS curves reached plateaus at 53
and 58 months after ASCT, respectively.
In high risk patients, the median PFS was 58.4
months (OS did not reach median) and, OS and
PFS rates at 5 years were 52.8% (95% CI: 39.2-
66.4%) and 37.8% (95% CI: 20.0-55.6%), respec-
tively. In sensitive-relapse patients, median OS
and PFS were 19.3 months and 4 months and,
OS and PFS rates at 5 years were 24.3% (95% CI:
5.6-43.0%) and 25.0% (95% CI: 12.5-37.5%), re-
spectively. In resistant-relapsed patients, the
median OS and PFS were both 3.4 months. In
primary refractory patients, median OS and PFS
were both 2.7 months. The patients who were
refractory had shorter OS and PFS than high risk
patients and relapsed patients (OS: p = 0.03, PFS:
p = 0.11). High risk patients and sensitive-relapse
patients did not show significant difference in OS
and PFS rates (OS: p = 0.28, PFS: p = 0.09) (Fig. 2.
A and B). In sensitive-relapse patients, those who
remained in CR 3 months after ASCT had better
OS and PFS than who were recurred (OS: p =
0.03, PFS: p = 0.001).
Fig. 2. (A) Overall survival rates according to disease status at transplantation. High risk vs. Resistant relapse, p = 0.37;
Sensitive relapse vs. Resistant relapse, p = 0.68. (B) Progression free survival rates according to disease status at
transplantation. High risk vs. Resistant relapse, p = 0.59; Sensitive relapse vs. Resistant relapse, p = 0.85.
Fig. 1. Overall survival ( ) and progression free survival
(---) rates of all patients.
A B
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Analysis of prognostic factors
The following characteristics were included in
the analysis of prognostic factors: age, histology,
Ann Arbor stage, bone marrow involvement,
number of extra nodal sites, and performance
status (ECOG) at diagnosis. Also included were
serum concentration of LDH, age-adjusted-IPI,
serum concentration of beta-2 microglobulin,
serum concentration of albumin, the presence of
B-symptom, and the presence of bulky mass (>
10 cm) at diagnosis and transplantation. Response
to initial chemotherapy, number of prior chemo-
therapy regimens, chemotherapy sensitivity,
disease status at transplantation and interval from
diagnosis to transplantation were other prognostic
factors considered.22 In the univariate analysis, 2
factors [Age at the diagnosis ( 45 years vs. > 45
years), ECOG at diagnosis (0 or 1 vs. 2)] for all
patients were significant (Age at the diagnosis,
OS: p = 0.01 and PFS: p = 0.01, ECOG, OS: p = 0.007
and PFS: p = 0.01). In multivariate analysis, age at
diagnosis was significant value for OS (p = 0.042)
and, ECOG at diagnosis was significant for PFS (p
= 0.046). In high risk patients who achieved CR
after induction therapy, the interval from first CR
to transplantation was prognostic factor for OS (p
= 0.048) (Fig. 3). The other factors were not signifi-
cant for OS and PFS in survival analysis.
DISCUSSION
NHL, especially diffuse large cell lymphoma is
highly chemo-sensitive malignancy. Treatment
with conventional chemotherapy yields CR rates
of 50-70% and disease-free survival (DFS) rates of
about 50%. However, 50-60% of patients are
refractory to initial therapy or relapse from CR.14
Under ordinary circumstances, less than 10% of
patients with relapsed lymphoma can be cured
with conventional salvage chemotherapy. HDC
with ASCT have been reported to improve pro-
gnosis in this cohort of patients and widely used
for patients with a sensitive relapse.23 For high
risk patients who had achieved CR after four
courses of induction treatment, the LNH87-2 study
reported that HDC with ASCT benefits patients at
higher risk according to the age- adjusted IPI who
achieve CR after induction therapy.
In our study in Korea, the overall survival and
progression free survival rates for the 40 patients
of aggressive NHL were 53% and 52% at 2 years,
respectively, and were 40% and 30% at 5 years
and, 40% and 30% at 8 years, respectively. These
are higher survival rates than those reported by
Kim et al. for Koreans (OS and PFS at 2 years: 48%
and 31%, respectively) and Shim et al. (OS and
PFS at 2 years: 52% and 36%, respectively).
24,25
In Western countries, the GEL-TAMO study
showed the OS and DFS rates of 452 NHL patients
treated with ASCT to be 53% and 43% at 5 years,
and Dowling et al. reported a 5-year OS and PFS
rates of 44% and 34% in 67 patients, respectively.26
The prognostic significance of a T-cell immuno-
phenotype has been addressed and it is generally
accepted that the T-cell immunophenotype confers
an adverse prognosis, independent of IPI.27 T-cell
NHL is rare in Europe and the United States,
where it constitutes about 15-20% of aggressive
lymphoma.28
In the Dowling et al. study, the proportion of
the B-cell to T-cell subtype was 76%: 12%. On the
other hand, T-cell NHL is more common in
Fig. 3. Overall survival rates according to interval from
CR to transplantation in high risk patients.
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Taiwan (24.5%) and Japan (24.9%).28,29 In Korea
the incidence of T cell lymphoma is assumed to
be about 25-38% (in our study: 27.5%, in Hahn et
al.`s study: 38%).30,31 We speculate that the lower
survival rates of ASCT in our study were due to
the higher frequency of the T cell subtype as com-
pared to other studies in the Western countries.
Rodriguez et al. suggested that the poor pro-
gnostic implication of the T-cell immunopheno-
type can be overcome with ASCT, and that future
clinical trials are needed to determine whether
ASCT either in the salvage setting or as frontline
therapy can improve treatment outcome for T cell
lymphoma.27
The PARMA study reported that the treatment
of HDC with ASCT increases event-free and
overall survival in patients with chemotherapy-
sensitive NHL in relapse.8 We reported 5-year OS
and PFS rates of 24.3% and 25.0% for sensitive
relapse patients, respectively, and Mills et al.
reported those with chemo-sensitive but relapsed
disease as having an OS rate at 5 years of 32%.5
Even though high risk patients tended to show
slightly longer survival time than the sensitive
relapse patients, and much better survival than
the resistant relapse patients, there was no statis-
tically significant difference between the three
groups. Further study will be needed with a
larger number of patients.
In this study, the OS and PFS rates for high risk
patients was 52.8% and 37.8% at 5 year, respec-
tively. Santini et al. reported OS and PFS of 65%
and 60% at 6 years for 63 patients who received
VACOP-B (etoposide, doxorubicin, cyclophospha-
mide, vincristine, predisolone, bleomycin) for 12
weeks plus HDC with ASCT, independent of dis-
ease status at the end of VACOP-B.10 Twenty-one
high risk patients in our study received ASCT as
consolidation in the first CR after full-length
induction treatment and showed 5-year OS and
PFS rates of 46% and 25%, respectively. The LNH
87-2 study reported 8-year disease-free survival
rates was 55% and 8-year OS rates was 64% in
high risk NHL.9
In our study, the median interval between
diagnosis and stem cell infusion in high risk
patients was 28 weeks, whereas those of Hauioun
et al. and Santini et al. were 19 and 18 weeks,
respectively.9,10 Several reports suggest that ASCT
is most effective when performed after maximal
cytoreduction.32 Gisselbrecht et al. showed that the
shortened standard induction therapy followed by
HDC with ASCT has not shown to benefit event-
free and overall survival rates, and Maurizio et al.
showed that the abbreviated induction therapy
and HCD with ASCT does not significantly im-
prove survival in patients with high risk aggres-
sive NHL.13,33 On the other hand, Milpied et al.
reported that up-front intensive chemotherapy
with ASCT is superior to CHOP for lymphoma
patients under 60 years old who have high inter-
mediate risk according to the age-adjusted-IPI. In
the HOVON-40 trials, up-front high-dose, sequen-
tial chemotherapy with intensified CHOP and
ASCT improved the duration of response and
survival of poor risk aggressive NHL patients (OS
at 4 years: 50%, disease-free survival at 4 years:
74%).34,35 Further clinical trial are needed to an-
alyze the optimal intensive therapy regimes and
the timing for transplantation to overcome
chemotherapy resistance and acquire the adequate
chemotherapy-based debulking.
There were three patients in our study who
failed to achieve CR after induction therapy but
were chemotherapy-sensitive. At a 5-year follow-
up, two patients were alive without disease, but
the other had died due to disease progression. In
the study by Vose et al., patients who never
achieved CR but who were still chemotherapy-
sensitive had PFS and OS rates of 31% and 37%
at 5 years, respectively.36 Rodriguez et al. re-
ported OS rates at 5 years as 43% and disease free
survival rates at 5 years as 63% for CR responders
after ASCT in diffuse large B-cell NHL not
achieving CR after induction therapy.37 These
results pointed to the benefit of using HDC with
ASCT in patients achieving PR after induction
chemotherapy.36
For twenty-four DLBCL patients (60%) treated
with ASCT, OS rates at 2 and 5 years was 43%
and 28.7%, and PFS rates at 2 and 5 years was
47% and 31.3%, respectively. In our study, twelve
DLBCL patients were transplanted as consolida-
tion after CR, in which OS and PFS rates at 2
years were 68.7% and 78.5%. Mounier et al.
reported OS and PFS in DLBCL patients treated
by front-line ASCT after CR were 68% and 76%
at 5 years respectively.38 Other 12 DLBCL relapsed
Autologous Stem Cell Transplantation in Non-Hodgkin’s Lymphoma
Yonsei Med J Vol. 47, No. 5, 2006
/refractory patients showed OS and PFS were
20.8% and 16.6% at 2 years, respectively and same
rate at 5 years in our study.
In the European CUP trial, HDC with ASCT
was more effective than the standard treatment
with regard to OS and PFS in relapsed patients
with follicular lymphoma.16 Noel et al. reported
that long-term and durable remission may be seen
in selected patients with low-grade NHL, espe-
cially in those with a low IPI score and chemo-
sensitive relapse.17 As of 30 July 2004, two of the
three in our study were in sustained CR, whereas
one patient had relapsed at 53 months after trans-
plantation and died due to the disease progres-
sion. The data on myeloablative therapy followed
by ASCT in follicular lymphoma are encouraging
and further clinical trials for follicular lymphoma
should reevaluate the role of ASCT.39
The outcome for patients with primary-refrac-
tory disease is very poor. Other studies’ results
were similar to ours, confirming that ASCT is not
proper for these patients and that a new treatment
strategy is needed for them. Such treatments may
include standard or nonmyeloablative allogeneic
stem cell transplantation even though the positive
result in the T-NK cell lymphoma case had
already been reported in our institution after the
nonmyeloablative allogeneic transplantation.5,37,40
The finding that older age (> 45 years) and poor
performance statuses are significant adverse
prognostic factors in NHL is consistent with other
studies.13,22,23 The interval between the first CR
and transplantation also influences the OS in high
risk patients who achieved CR after induction
therapy. This suggests that high risk patients con-
sidered as candidates for HDT with ASCT should
undergo transplantation early in the course of the
disease after the first CR.23 The rationale for
reducing the interval between CR and transplan-
tation is to overcome chemotherapy resistance on
a tight schedule, following one as shortly after the
other as possible.35
In our study, two of the relapsed patients, all
of the primary-refractory disease patients and
three of the high risk patients received the in-
volved field radiotherapy (IFR). Three of seven
who received IFR remain alive in continuous CR
at the last follow-up. Several recent studies have
demonstrated the method of 'involved-field'
radiation as a treatment modality in lymphoma to
minimize disease bulk before transplants, to
reduce relapse rates at sites of prior disease at the
time of the transplant or after the transplant in
either a CR state or persistent disease.41,42 Al-
though few patients were irradiated in our study
so as to allow a meaningful analysis, IFR should
be considered in the design of future HDC with
ASCT in aggressive NHL patients.
In conclusion, transplantation in high risk NHL
patients who have achieved a prior response to
complete standard induction treatment should be
performed early to avoid chemo-resistance; and
treatment with ASCT is not appropriate for
primary-refractory patients, who should be
treated by novel strategies.
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